Patient Blood Type Is Associated With Response to Immune Checkpoint Blockade in Metastatic Cancer.

ABSTRACT:

Background

Immune checkpoint blockade (ICB) has transformed cancer therapy, with long-term responses and a favorable safety profile; however, only a minority of patients respond. Response to ICB is influenced by immune-related genetic factors such as HLA haplotype, potentially including patient blood type and associated differences in diversity of the T-cell repertoire. A minority of patients experience immune-related adverse events (irAEs), with unclear relation to response or resistance.

Materials and methods

In this single institution study, we aimed to investigate the relationship of time to treatment failure (TTF) with patient blood type and with occurrence of irAEs, among patients with metastatic cancer receiving ICB.

Results

We found a strong association of imp

SUBMITTER: Chen R 

PROVIDER: S-EPMC9438912 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature